Cyclophosphamide (Endoxan) and immunochemotherapy

Exemestane (aromasin) for and Cyclophosphamide (endoxan) for Metastatic Breast Cancer (correctie)

Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane (Endoxan) may fight breast cancer by blocking the use of estrogen by the tumor cells. Low dose cyclophosphamide (for example 50 mg) may also stimulate the white blood cells, including natural killer cells, for instance by decreasing the suppressor (regulatory) T-cells. Giving exemestane (Endoxan) with cyclophosphamide may be an effective treatment for estrogen receptor-positive, progesterone receptor-positive, and HER2-negative stage IV breast cancer.

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085883/)

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.

The immunity is dual host-protective and tumor-promoting in cancer development and progression. Many immune suppressive cells and cytokines in microenvironment can prevent cytotoxic T lymphocytes (CTL) and natural killer cells (NK) from killing tumor cells. Chemotherapy drugs and irradiation have been reported helpful in breaking immune tolerance and creating microenvironment for ADOPTIVE cell therapy. Low-dose cyclophosphamide or gemcitabine therapy can selectively deplete T regulatory cells (Treg).

Jinan Central Hospital affiliated to Shandong University, No. 105, Jie Fang Road, Jinan, Shandong 250013, China.

© kanker gezond(er) benaderen 2015.